Nadia Gracias represents clients in the life-sciences, technology, and healthcare sectors on the commercialisation of cutting-edge technologies. She has extensive experience in advising on all aspects of IP commercialisation strategy including development, licensing, collaboration, R&D deals and university spin-offs. She counsels clients on regulatory risks in the life sciences and health-tech sectors in an M&A and early-stage financing context, across all stages of the drug/device development life cycle. In 2020 Nadia was involved in advising on several projects (prophylactic, therapeutic and diagnostic) that were critical to delivering Covid-19 healthcare solutions both in the UK and overseas.

Nadia has significant pharmaceutical industry experience gained during four years in-house with a global CRO, advising on regulatory and contractual aspects of all phases of clinical trials, with a particular focus on oncology and paediatric trials. She has advised on the IP, commercial and regulatory aspects of the purchase of the largest public sector clinical trials unit in the UK. Nadia also spent time in the public sector working with the global IP legal team for 15 international agricultural research institutes funded by the UN Food and Agriculture Organisation and the World Bank.

Nadia is a qualified as a Solicitor in England and an Advocate in India. She holds a degree in international commercial law from the University of Cambridge and a post graduate degree in intellectual property law from the University of Oxford. She was a Cambridge Commonwealth Scholar, as well as an incoming Pegasus scholar with the Inner Temple in London, and served as a judicial clerk with the Supreme Court of India. She also acts as a mentor to a number of early stage start-ups and accelerator programs.


Protecting Data in Digital Health and Connected Devices (US & Europe Privacy, IP, Transactions)
AdvaMed Webinar
Chambers Global Practice Guide: Life Sciences 2022 (pdf)
Chambers and Partners, UK
Update on the European Commission’s Proposed New Pharmaceutical Strategy
BioSlice Blog

Email Disclaimer